Nanobiotix Responds to Acquisition Speculation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 25 2026
0mins
Should l Buy NBTX?
Source: Newsfilter
- Acquisition Rumor Clarification: Nanobiotix has stated that there is no intention to acquire control of the company in response to recent media speculation, ensuring investor confidence regarding the company's governance.
- Inaccurate Media Reporting: The company highlighted factual inaccuracies in the media reports that are inconsistent with its latest public disclosures, emphasizing the importance of transparency and information accuracy to maintain its reputation and investor trust.
- Technological Platform Strength: Nanobiotix owns over 30 patents associated with three major nanotechnology platforms, covering oncology, bioavailability, and central nervous system disorders, showcasing its innovative capabilities and competitive edge in the biotechnology sector.
- Company Background: Founded in 2003 and headquartered in Paris, Nanobiotix has been listed on Euronext Paris since 2012 and on Nasdaq since 2020, reflecting its global development strategy and commitment to improving human health.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBTX
Wall Street analysts forecast NBTX stock price to fall
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 32.460
Low
3.50
Averages
3.50
High
3.50
Current: 32.460
Low
3.50
Averages
3.50
High
3.50
About NBTX
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nanobiotix Unveils Preclinical Data for Nanoprimer Platform
- Preclinical Data Release: Nanobiotix presented preclinical data for its Nanoprimer platform at the American Association for Cancer Research annual meeting, showcasing its potential applications in lipid nanoparticle-delivered recombinant DNA, which could open new avenues in cancer treatment.
- Enhanced Bioavailability: Administering LNP-DNA intravenously in mouse models with Nanoprimer significantly reduced hepatic uptake and toxicity while increasing circulating levels of LNP-DNA, thereby improving drug bioavailability and patient treatment outcomes.
- Broad Application Potential: The positive preclinical results indicate that Nanoprimer has extensive applications in LNP-DNA formulations, RNA delivery, gene therapies, and advanced biologics, potentially transforming existing treatment modalities.
- Positive Market Reaction: NBTX shares closed up 4.10% at $33.79 last Friday, reflecting strong market expectations and increased investor confidence in the company's innovative technology.
See More
Nanobiotix's Nanoprimer Enhances LNP-DNA Delivery for Cancer Therapy
- Increased Bioavailability: Pre-treatment with Nanoprimer in mouse models significantly enhances the systemic bioavailability of LNP-DNA, indicating its potential to effectively overcome liver clearance issues associated with lipid nanoparticle therapies, thereby improving the efficacy of anti-tumor immunotherapy.
- Reduced Hepatic Toxicity: The study demonstrates that the application of Nanoprimer decreases liver uptake and toxicity of LNP-DNA, improving hepatic tolerability, which is crucial for enhancing patient safety during treatment.
- Mitigated Inflammatory Response: The pre-treatment with Nanoprimer attenuates the activation of the cGAS-STING pathway, reducing related inflammatory responses, which may contribute to improved overall treatment outcomes and minimized side effects.
- Broad Applicability: The potential applications of Nanoprimer extend beyond the current LNP-DNA designs, suggesting it could optimize other advanced drug delivery systems, thereby supporting future applications across multiple drug classes and advancing biotechnological innovations.
See More
Nanobiotix Reports Narrowed Net Loss and Cash Runway Guidance
- Improved Financial Performance: In 2025, Nanobiotix reported a narrowed net loss of €23.96 million, or €0.50 per share, down from €68.13 million and €1.44 per share the previous year, indicating progress in financial management despite ongoing losses.
- Significant Revenue Growth: The company achieved revenue and other income of €32.59 million in 2025, a substantial improvement from a negative €7.19 million in the prior year, which included a one-off positive revenue recognition of €21.8 million under IFRS15, reflecting increased market acceptance of its products.
- Strategic Financing Agreement: Nanobiotix entered into a non-dilutive royalty monetization agreement with HealthCare Royalty for up to $71 million, of which $50 million was received in December 2025, providing crucial funding support expected to extend operations into 2028.
- Clinical Data Outlook: Clinical data readouts for JNJ-1900 are anticipated in 2026, covering NSCLC, pancreatic cancer, melanoma, and esophageal cancer, and positive results could further enhance the company's market position in cancer treatment.
See More
Nanobiotix Reports FY 2025 Financial Results
- Financial Performance: Nanobiotix reported a FY 2025 GAAP EPS of -€0.50 with revenues of €29.6 million, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, Nanobiotix had €52.8 million in cash and cash equivalents, an increase from €49.7 million in 2024, reflecting improved cash management practices.
- Financial Guidance: The company anticipates that its current cash reserves will fund operations into early 2028, contingent upon receiving the remaining $21 million funding from HCRx expected one year post-closing, providing a buffer for ongoing operations.
- Milestone Funding: This cash flow forecast excludes any milestone receipts, indicating that the company will still rely on external financing for future cash inflows, which adds to its financial risk.
See More
Nanobiotix Presents Lung Cancer Study Data at ELCC 2026
- Clinical Trial Results: At the 2026 European Lung Cancer Conference, Nanobiotix presented initial data from the Johnson & Johnson-sponsored CONVERGE study, showing a promising objective response rate (ORR) of 71.4% for JNJ-1900 in patients with stage III inoperable non-small cell lung cancer, significantly exceeding the expected benchmark of 45%-50%.
- Safety Assessment: The study demonstrated an acceptable safety profile for JNJ-1900, with no serious treatment-emergent adverse events (TEAEs), which supports its further clinical application and enhances patients' ability to continue planned therapies.
- Innovative Mechanism of Action: JNJ-1900 is a novel oncology product designed to induce significant tumor cell death through a one-time intratumoral injection activated by radiotherapy, potentially applicable to any solid tumor treatable with radiotherapy, thus expanding its therapeutic potential.
- Collaborative Development Strategy: Nanobiotix has entered into a global co-development and commercialization agreement for JNJ-1900 with Janssen Pharmaceutica, a Johnson & Johnson company, indicating a strategic focus on oncology and aiming to accelerate product development through partnerships with leading research institutions.
See More
Nanobiotix to Report Q4 and FY2025 Financial Results
- Financial Reporting Schedule: Nanobiotix will release its financial results for the fiscal year and fourth quarter of 2025 on March 31, 2026, after the U.S. market closes, which is expected to positively impact the company's future outlook.
- Conference Call Details: The company will hold a conference call on April 1, 2026, at 8:00 AM EDT, where CEO Laurent Levy and CFO Bart van Rhijn will review financial results and update business activities, thereby enhancing investor confidence.
- Technological Innovation Focus: Nanobiotix specializes in nanoparticle-based therapeutic approaches aimed at improving treatment outcomes for cancer and other major diseases, holding over 30 patent families, which underscores its leadership in the biotechnology sector.
- Company Development History: Founded in 2003, Nanobiotix has established subsidiaries in Paris and Cambridge, and has been listed on Euronext Paris since 2012 and on Nasdaq since 2020, demonstrating its strategic global expansion efforts.
See More
Nanobiotix Unveils Preclinical Data for Nanoprimer Platform
- Preclinical Data Release: Nanobiotix presented preclinical data for its Nanoprimer platform at the American Association for Cancer Research annual meeting, showcasing its potential applications in lipid nanoparticle-delivered recombinant DNA, which could open new avenues in cancer treatment.
- Enhanced Bioavailability: Administering LNP-DNA intravenously in mouse models with Nanoprimer significantly reduced hepatic uptake and toxicity while increasing circulating levels of LNP-DNA, thereby improving drug bioavailability and patient treatment outcomes.
- Broad Application Potential: The positive preclinical results indicate that Nanoprimer has extensive applications in LNP-DNA formulations, RNA delivery, gene therapies, and advanced biologics, potentially transforming existing treatment modalities.
- Positive Market Reaction: NBTX shares closed up 4.10% at $33.79 last Friday, reflecting strong market expectations and increased investor confidence in the company's innovative technology.
See More
Nanobiotix's Nanoprimer Enhances LNP-DNA Delivery for Cancer Therapy
- Increased Bioavailability: Pre-treatment with Nanoprimer in mouse models significantly enhances the systemic bioavailability of LNP-DNA, indicating its potential to effectively overcome liver clearance issues associated with lipid nanoparticle therapies, thereby improving the efficacy of anti-tumor immunotherapy.
- Reduced Hepatic Toxicity: The study demonstrates that the application of Nanoprimer decreases liver uptake and toxicity of LNP-DNA, improving hepatic tolerability, which is crucial for enhancing patient safety during treatment.
- Mitigated Inflammatory Response: The pre-treatment with Nanoprimer attenuates the activation of the cGAS-STING pathway, reducing related inflammatory responses, which may contribute to improved overall treatment outcomes and minimized side effects.
- Broad Applicability: The potential applications of Nanoprimer extend beyond the current LNP-DNA designs, suggesting it could optimize other advanced drug delivery systems, thereby supporting future applications across multiple drug classes and advancing biotechnological innovations.
See More
Nanobiotix Reports Narrowed Net Loss and Cash Runway Guidance
- Improved Financial Performance: In 2025, Nanobiotix reported a narrowed net loss of €23.96 million, or €0.50 per share, down from €68.13 million and €1.44 per share the previous year, indicating progress in financial management despite ongoing losses.
- Significant Revenue Growth: The company achieved revenue and other income of €32.59 million in 2025, a substantial improvement from a negative €7.19 million in the prior year, which included a one-off positive revenue recognition of €21.8 million under IFRS15, reflecting increased market acceptance of its products.
- Strategic Financing Agreement: Nanobiotix entered into a non-dilutive royalty monetization agreement with HealthCare Royalty for up to $71 million, of which $50 million was received in December 2025, providing crucial funding support expected to extend operations into 2028.
- Clinical Data Outlook: Clinical data readouts for JNJ-1900 are anticipated in 2026, covering NSCLC, pancreatic cancer, melanoma, and esophageal cancer, and positive results could further enhance the company's market position in cancer treatment.
See More
Nanobiotix Reports FY 2025 Financial Results
- Financial Performance: Nanobiotix reported a FY 2025 GAAP EPS of -€0.50 with revenues of €29.6 million, indicating challenges in profitability that may affect investor confidence.
- Cash Position: As of December 31, 2025, Nanobiotix had €52.8 million in cash and cash equivalents, an increase from €49.7 million in 2024, reflecting improved cash management practices.
- Financial Guidance: The company anticipates that its current cash reserves will fund operations into early 2028, contingent upon receiving the remaining $21 million funding from HCRx expected one year post-closing, providing a buffer for ongoing operations.
- Milestone Funding: This cash flow forecast excludes any milestone receipts, indicating that the company will still rely on external financing for future cash inflows, which adds to its financial risk.
See More
Nanobiotix Presents Lung Cancer Study Data at ELCC 2026
- Clinical Trial Results: At the 2026 European Lung Cancer Conference, Nanobiotix presented initial data from the Johnson & Johnson-sponsored CONVERGE study, showing a promising objective response rate (ORR) of 71.4% for JNJ-1900 in patients with stage III inoperable non-small cell lung cancer, significantly exceeding the expected benchmark of 45%-50%.
- Safety Assessment: The study demonstrated an acceptable safety profile for JNJ-1900, with no serious treatment-emergent adverse events (TEAEs), which supports its further clinical application and enhances patients' ability to continue planned therapies.
- Innovative Mechanism of Action: JNJ-1900 is a novel oncology product designed to induce significant tumor cell death through a one-time intratumoral injection activated by radiotherapy, potentially applicable to any solid tumor treatable with radiotherapy, thus expanding its therapeutic potential.
- Collaborative Development Strategy: Nanobiotix has entered into a global co-development and commercialization agreement for JNJ-1900 with Janssen Pharmaceutica, a Johnson & Johnson company, indicating a strategic focus on oncology and aiming to accelerate product development through partnerships with leading research institutions.
See More
Nanobiotix to Report Q4 and FY2025 Financial Results
- Financial Reporting Schedule: Nanobiotix will release its financial results for the fiscal year and fourth quarter of 2025 on March 31, 2026, after the U.S. market closes, which is expected to positively impact the company's future outlook.
- Conference Call Details: The company will hold a conference call on April 1, 2026, at 8:00 AM EDT, where CEO Laurent Levy and CFO Bart van Rhijn will review financial results and update business activities, thereby enhancing investor confidence.
- Technological Innovation Focus: Nanobiotix specializes in nanoparticle-based therapeutic approaches aimed at improving treatment outcomes for cancer and other major diseases, holding over 30 patent families, which underscores its leadership in the biotechnology sector.
- Company Development History: Founded in 2003, Nanobiotix has established subsidiaries in Paris and Cambridge, and has been listed on Euronext Paris since 2012 and on Nasdaq since 2020, demonstrating its strategic global expansion efforts.
See More
